FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

23

Therapeutic area intelligence for 23 with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 3

Companies

Accord Biopharma →

Amgen →

Centocor Ortho Biotech →

Assets

Recent signals(4)

RegulatoryJuly 27, 2026

FDA Accepts Supplement for STELARA (Ustekinumab) by Centocor Ortho Biotech

The FDA has accepted a supplemental application for STELARA (ustekinumab) from Centocor Ortho Biotech.

RegulatoryJuly 15, 2026

FDA Accepts Supplement Application for WEZLANA (Ustekinumab-Auub) by Amgen

The FDA has accepted the supplemental application for WEZLANA, an IL-12/23 inhibitor.

RegulatoryJuly 4, 2026

FDA Accepts Supplement Application for STELARA by Janssen Biotech

The FDA has accepted a supplemental application for STELARA (ustekinumab) from Janssen Biotech.

RegulatoryJune 20, 2026

FDA Accepts Supplement Application for IMULDOSA by Accord Biopharma

The FDA has accepted the supplemental application for IMULDOSA (USTEKINUMAB-SRLF) from Accord Biopharma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.